Reported Friday, Cellectar Biosciences Announces Plan To Restate Financials, Delays 10-Q Filing, And Receives Nasdaq Non-Compliance Notification
Reported Friday, Cellectar Biosciences Announces Plan To Restate Financials, Delays 10-Q Filing, And Receives Nasdaq Non-Compliance Notification
Cellectar Biosciences于周五宣布计划重新报表财务数据，延迟提交10-Q文件，并收到纳斯达克非合规通知
- The Notice indicated that the Company is not in compliance with the periodic financial report filing requirement set forth in Nasdaq Listing Rule 5250(c)(1) as a result of the Company's delay in filing its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (the "Second Quarter 10-Q"), by the applicable due date.
- The delay in filing the Second Quarter 10-Q is a result of the Company's need to restate certain previously filed financial statements.
- 此通知指出，由于未按规定的纳斯达克上市规则5250(c)(1)提交定期财务报告的要求，公司未能按照规定的截止日期前提交截至2024年6月30日的季度报告第10-Q（"第二季度10-Q"）。
- 延迟提交第二季度10-Q的原因是因为公司需要对先前提交的某些财务报表进行重述。